Table 4.

Univariable progression-free survival analysis with proportional hazard regression in CRC patients with chemotherapy containing cetuximab.

Prognostic variable	Hazard ratio	95%CI	p-value
Age (≤65 yr vs. >65 yr)	0.980	0.672-1.428	0.915
Gender (Male vs. Female)	1.008	0.851-1.193	0.930
Primary site (Lt. side vs. Rt. side)	1.264	0.825-1.936	0.282
No. of metastatic site (1 vs. 1<)	1.205	0.865-1.680	0.270
KRAS status (Wild vs. Mutant)	1.331	0.751-2.360	0.328
BRAF status (Wild vs. Mutant) (n=72)	1.029	0.442-2.395	0.947
Microsatellite instability (MSS vs. MSI)	1.277	0.845-1.931	0.245